Provided by Tiger Fintech (Singapore) Pte. Ltd.

Progenics Pharmaceuticals

4.10
+0.0000
Volume:- -
Turnover:- -
Market Cap:355.05M
PE:-5.30
High:4.10
Open:4.10
Low:4.10
Close:4.10
Loading ...
Aug 28, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
Aug 27, 2019

Statement Of Changes In Beneficial Ownership

Initial statement of beneficial ownership of securities
Aug 26, 2019

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Aug 09, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Aug 09, 2019

Major Issues Report

Current report, items 2.02, 7.01, and 9.01
Aug 08, 2019

Major Issues Report

Current report, item 5.02
Aug 06, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Aug 05, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Jul 22, 2019

Major Issues Report

[Amend] Current report, item 5.07
Jul 18, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Jul 17, 2019

Major Issues Report

Current report, item 5.07
Jul 15, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 15, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 15, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 15, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities